APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Virus Attenuated Live Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Varicella Virus Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchVaricella Virus Attenuated Live Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Virus Attenuated Live Vaccine Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Varicella Virus Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Virus Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Virus Attenuated Live Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Varicella Virus Attenuated Live Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Varicella Virus Attenuated Live Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Varicella Virus Attenuated Live Vaccine market include GSK, Changsheng, Sanofi, Merck, Biken, Shanghai Institute, Keygen, Green Cross and BCHT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Varicella Virus Attenuated Live Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Virus Attenuated Live Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Virus Attenuated Live Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Virus Attenuated Live Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Virus Attenuated Live Vaccine Segment by Company

GSK

Changsheng

Sanofi

Merck

Biken

Shanghai Institute

Keygen

Green Cross

BCHT

Varicella Virus Attenuated Live Vaccine Segment by Type

Child

Adult

Varicella Virus Attenuated Live Vaccine Segment by Application

Government Institution

Private Sector

Other

Varicella Virus Attenuated Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Varicella Virus Attenuated Live Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Varicella Virus Attenuated Live Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Varicella Virus Attenuated Live Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Varicella Virus Attenuated Live Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Virus Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Virus Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Virus Attenuated Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Virus Attenuated Live Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Varicella Virus Attenuated Live Vaccine industry.

Chapter 3: Detailed analysis of Varicella Virus Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Varicella Virus Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Varicella Virus Attenuated Live Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Varicella Virus Attenuated Live Vaccine Industry Trends Table 2. Varicella Virus Attenuated Live Vaccine Industry Drivers Table 3. Varicella Virus Attenuated Live Vaccine Industry Opportunities and Challenges Table 4. Varicella Virus Attenuated Live Vaccine Industry Restraints Table 5. Global Varicella Virus Attenuated Live Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Varicella Virus Attenuated Live Vaccine Revenue Share by Company (2021-2026) Table 7. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Varicella Virus Attenuated Live Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Varicella Virus Attenuated Live Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Varicella Virus Attenuated Live Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Varicella Virus Attenuated Live Vaccine Company, Product Type & Application Table 13. Global Varicella Virus Attenuated Live Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Virus Attenuated Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Child Table 18. Significant Companies of Adult Table 19. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Varicella Virus Attenuated Live Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Varicella Virus Attenuated Live Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Varicella Virus Attenuated Live Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Government Institution Table 30. Significant Companies of Private Sector Table 31. Significant Companies of Other Table 32. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Application (2021-2026) & (k units) Table 34. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Application (2027-2032) & (k units) Table 35. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Varicella Virus Attenuated Live Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Varicella Virus Attenuated Live Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Varicella Virus Attenuated Live Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Varicella Virus Attenuated Live Vaccine Sales by Region (2021-2026) & (k units) Table 44. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Varicella Virus Attenuated Live Vaccine Sales by Region (2027-2032) & (k units) Table 46. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Varicella Virus Attenuated Live Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Varicella Virus Attenuated Live Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Varicella Virus Attenuated Live Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Varicella Virus Attenuated Live Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Varicella Virus Attenuated Live Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Varicella Virus Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Varicella Virus Attenuated Live Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 57. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 59. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Varicella Virus Attenuated Live Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Varicella Virus Attenuated Live Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Varicella Virus Attenuated Live Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Varicella Virus Attenuated Live Vaccine Sales Value Market Share by Country (2027-2032) Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. GSK Varicella Virus Attenuated Live Vaccine Product Portfolio Table 68. GSK Recent Development Table 69. Changsheng Company Information Table 70. Changsheng Business Overview Table 71. Changsheng Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Changsheng Varicella Virus Attenuated Live Vaccine Product Portfolio Table 73. Changsheng Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sanofi Varicella Virus Attenuated Live Vaccine Product Portfolio Table 78. Sanofi Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Merck Varicella Virus Attenuated Live Vaccine Product Portfolio Table 83. Merck Recent Development Table 84. Biken Company Information Table 85. Biken Business Overview Table 86. Biken Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Biken Varicella Virus Attenuated Live Vaccine Product Portfolio Table 88. Biken Recent Development Table 89. Shanghai Institute Company Information Table 90. Shanghai Institute Business Overview Table 91. Shanghai Institute Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Shanghai Institute Varicella Virus Attenuated Live Vaccine Product Portfolio Table 93. Shanghai Institute Recent Development Table 94. Keygen Company Information Table 95. Keygen Business Overview Table 96. Keygen Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Keygen Varicella Virus Attenuated Live Vaccine Product Portfolio Table 98. Keygen Recent Development Table 99. Green Cross Company Information Table 100. Green Cross Business Overview Table 101. Green Cross Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Green Cross Varicella Virus Attenuated Live Vaccine Product Portfolio Table 103. Green Cross Recent Development Table 104. BCHT Company Information Table 105. BCHT Business Overview Table 106. BCHT Varicella Virus Attenuated Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. BCHT Varicella Virus Attenuated Live Vaccine Product Portfolio Table 108. BCHT Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Varicella Virus Attenuated Live Vaccine Distributors List Table 112. Varicella Virus Attenuated Live Vaccine Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Varicella Virus Attenuated Live Vaccine Product Image Figure 2. Global Varicella Virus Attenuated Live Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Varicella Virus Attenuated Live Vaccine Sales (2021-2032) & (k units) Figure 5. Global Varicella Virus Attenuated Live Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Varicella Virus Attenuated Live Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Child Image Figure 10. Adult Image Figure 11. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Varicella Virus Attenuated Live Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Varicella Virus Attenuated Live Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Type (2021-2032) Figure 17. Government Institution Image Figure 18. Private Sector Image Figure 19. Other Image Figure 20. Global Varicella Virus Attenuated Live Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Varicella Virus Attenuated Live Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Varicella Virus Attenuated Live Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Varicella Virus Attenuated Live Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Varicella Virus Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Varicella Virus Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Varicella Virus Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Varicella Virus Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Varicella Virus Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Varicella Virus Attenuated Live Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Varicella Virus Attenuated Live Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Government Institution
  • Private Sector
  • Other
Companies covered
  • GSK
  • Changsheng
  • Sanofi
  • Merck
  • Biken
  • Shanghai Institute
  • Keygen
  • Green Cross
  • BCHT

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Varicella Virus Attenuated Live Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Varicella Virus Attenuated Live Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Varicella Virus Attenuated Live Vaccine Market Dynamics
  1. 2.1 Varicella Virus Attenuated Live Vaccine Industry Trends
  2. 2.2 Varicella Virus Attenuated Live Vaccine Industry Drivers
  3. 2.3 Varicella Virus Attenuated Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Virus Attenuated Live Vaccine Industry Restraints
3 Varicella Virus Attenuated Live Vaccine Market by Company
  1. 3.1 Global Varicella Virus Attenuated Live Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Varicella Virus Attenuated Live Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Varicella Virus Attenuated Live Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Varicella Virus Attenuated Live Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Varicella Virus Attenuated Live Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Varicella Virus Attenuated Live Vaccine Company Product Type and Application
  8. 3.8 Global Varicella Virus Attenuated Live Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Varicella Virus Attenuated Live Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Varicella Virus Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Varicella Virus Attenuated Live Vaccine Market by Type
  1. 4.1 Varicella Virus Attenuated Live Vaccine Type Introduction
  2. 4.1.1 Child
  3. 4.1.2 Adult
  4. 4.2 Global Varicella Virus Attenuated Live Vaccine Sales Volume by Type
  5. 4.2.1 Global Varicella Virus Attenuated Live Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Virus Attenuated Live Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Varicella Virus Attenuated Live Vaccine Sales Value by Type
  9. 4.3.1 Global Varicella Virus Attenuated Live Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Virus Attenuated Live Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Type (2021-2032)
5 Varicella Virus Attenuated Live Vaccine Market by Application
  1. 5.1 Varicella Virus Attenuated Live Vaccine Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Other
  5. 5.2 Global Varicella Virus Attenuated Live Vaccine Sales Volume by Application
  6. 5.2.1 Global Varicella Virus Attenuated Live Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Varicella Virus Attenuated Live Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Varicella Virus Attenuated Live Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Varicella Virus Attenuated Live Vaccine Sales Value by Application
  10. 5.3.1 Global Varicella Virus Attenuated Live Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Varicella Virus Attenuated Live Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Varicella Virus Attenuated Live Vaccine Sales Value Share by Application (2021-2032)
6 Varicella Virus Attenuated Live Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Virus Attenuated Live Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Varicella Virus Attenuated Live Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Varicella Virus Attenuated Live Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Varicella Virus Attenuated Live Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Varicella Virus Attenuated Live Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Varicella Virus Attenuated Live Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Varicella Virus Attenuated Live Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Varicella Virus Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Varicella Virus Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Varicella Virus Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Varicella Virus Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Varicella Virus Attenuated Live Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Varicella Virus Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
7 Varicella Virus Attenuated Live Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Varicella Virus Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Varicella Virus Attenuated Live Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Varicella Virus Attenuated Live Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Varicella Virus Attenuated Live Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Varicella Virus Attenuated Live Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Varicella Virus Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Varicella Virus Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Varicella Virus Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Varicella Virus Attenuated Live Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Changsheng
  8. 8.2.1 Changsheng Company Information
  9. 8.2.2 Changsheng Business Overview
  10. 8.2.3 Changsheng Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Changsheng Varicella Virus Attenuated Live Vaccine Product Portfolio
  12. 8.2.5 Changsheng Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Varicella Virus Attenuated Live Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Varicella Virus Attenuated Live Vaccine Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Biken
  26. 8.5.1 Biken Company Information
  27. 8.5.2 Biken Business Overview
  28. 8.5.3 Biken Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Biken Varicella Virus Attenuated Live Vaccine Product Portfolio
  30. 8.5.5 Biken Recent Developments
  31. 8.6 Shanghai Institute
  32. 8.6.1 Shanghai Institute Company Information
  33. 8.6.2 Shanghai Institute Business Overview
  34. 8.6.3 Shanghai Institute Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Institute Varicella Virus Attenuated Live Vaccine Product Portfolio
  36. 8.6.5 Shanghai Institute Recent Developments
  37. 8.7 Keygen
  38. 8.7.1 Keygen Company Information
  39. 8.7.2 Keygen Business Overview
  40. 8.7.3 Keygen Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Keygen Varicella Virus Attenuated Live Vaccine Product Portfolio
  42. 8.7.5 Keygen Recent Developments
  43. 8.8 Green Cross
  44. 8.8.1 Green Cross Company Information
  45. 8.8.2 Green Cross Business Overview
  46. 8.8.3 Green Cross Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Green Cross Varicella Virus Attenuated Live Vaccine Product Portfolio
  48. 8.8.5 Green Cross Recent Developments
  49. 8.9 BCHT
  50. 8.9.1 BCHT Company Information
  51. 8.9.2 BCHT Business Overview
  52. 8.9.3 BCHT Varicella Virus Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 BCHT Varicella Virus Attenuated Live Vaccine Product Portfolio
  54. 8.9.5 BCHT Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Virus Attenuated Live Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Virus Attenuated Live Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Virus Attenuated Live Vaccine Sales Mode & Process
  6. 9.2 Varicella Virus Attenuated Live Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Virus Attenuated Live Vaccine Distributors
  9. 9.2.3 Varicella Virus Attenuated Live Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst